86 related articles for article (PubMed ID: 6489904)
21. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
22. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
23. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
[TBL] [Abstract][Full Text] [Related]
24. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
25. [A course of pirarubicin vesical irrigation at thirty mg effectively prevents post-TUR recurrence of superficial bladder cancer].
Kawamura S; Fujioka T; Kubo T; Yoshida I; Takata K
Gan To Kagaku Ryoho; 1996 Mar; 23(4):465-70. PubMed ID: 8678499
[TBL] [Abstract][Full Text] [Related]
26. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
27. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
[TBL] [Abstract][Full Text] [Related]
28. Tur vs TUR plus adriamycin in patients with superficial bladder cancer--a five-year follow-up.
Burk K; Schultze-Seemann W; Rodeck G
Prog Clin Biol Res; 1989; 303():417-22. PubMed ID: 2780656
[No Abstract] [Full Text] [Related]
29. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
30. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
31. Experiences on the local adriamycin treatment of bladder tumours.
Somogyi L; Török A; Bors G; Frang D
Acta Chir Hung; 1987; 28(2):79-85. PubMed ID: 3618056
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
35. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of 34 cases of infiltrating carcinoma of the bladder treated exclusively with partial cystectomy (part 1)].
Escudero Barrilero A; Fernández Fernández E; Jiménez Cidre M; Maganto Pavón E; Mayayo Dehesa T; Rodríguez Rodríguez R; Galvis San Juan F; Burgos Revilla FJ
Arch Esp Urol; 1996 May; 49(4):349-64. PubMed ID: 8754191
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
39. [The role of preserving therapy of invasive cancer of the urinary bladder].
Matveev BP; Sallum SD; Kamolov BSh; Figurin KM; Matveev VB; Volkova MI
Urologiia; 2005; (6):3-6. PubMed ID: 16419470
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
